
Ramaswamy S
2.1K posts

Ramaswamy S
@hurryram
Dreamer. Interested in science, science and society and methods of doing science and innovation. Tweeting here in personal capacity.












One step closer to market! As part of its ongoing clinical trials, @EyestemResearch, a CCAMP supported & incubated startup has completed the first round of patient injections for treatment of dry age-related macular degeneration (AMD)! 🔗modernretina.com/view/eyestem-c… AMD is a leading cause of blindness in individuals more than 60 years of age that impacts an estimated 196 million people globally Eyestem's Eyecyte-RPE is an affordable stem cell based therapy aimed at combating geographic atrophy arising from dry AMD 9 patients with very low vision will be treated in the 1st phase of the trial while the second phase will treat 27 patients with intermediate vision loss in order to determine efficacy @CCAMP_India @jogin_desai @DBTIndia @BIRAC_2012 @AIMtoInnovate @ITBTGoK @NITIAayog







Monsoons in Mumbai in the collonade of @TIFRScience




